Cargando…

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial

PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in systemic exposure and could therefore imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Rouw, Nikki, Boosman, René J., Burgers, Jacobus A., Huitema, Alwin D. R., Dingemans, Anne-Marie C., Derijks, Hieronymus. J., Burger, David M., Piet, Berber, Hendriks, Lizza E. L., Biesma, Bonne, Pruis, Melinda A., Dumoulin, Daphne W., Croes, Sander, Mathijssen, Ron H. J., van den Heuvel, Michel M., ter Heine, Rob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685043/ https://www.ncbi.nlm.nih.gov/pubmed/36413252 http://dx.doi.org/10.1007/s00280-022-04489-1

Ejemplares similares

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
por: de Rouw, Nikki, et al.
Publicado: (2021)

The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
por: de Rouw, Nikki, et al.
Publicado: (2022)

Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
por: van Ewijk‐Beneken Kolmer, Eleonora W. J., et al.
Publicado: (2021)

A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions
por: de Rouw, Nikki, et al.
Publicado: (2019)

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
por: ter Heine, Rob, et al.
Publicado: (2023)

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
por: Veerman, G.D. Marijn, et al.
Publicado: (2023)

Immunotherapy in small cell lung cancer: one step at a time: a narrative review
por: Dumoulin, Daphne W., et al.
Publicado: (2021)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
por: Meertens, Marinda, et al.
Publicado: (2023)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
por: Dumoulin, Daphne W., et al.
Publicado: (2020)

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment
por: Hendriks, Lizza E. L., et al.
Publicado: (2018)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review
por: Brouns, Anita, et al.
Publicado: (2021)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020)

Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy
por: van Genugten, Evelien A. J., et al.
Publicado: (2022)

Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases
por: Schoenmaekers, Janna J.A. O., et al.
Publicado: (2022)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
por: Verduyn, S Cora, et al.
Publicado: (2012)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Edema of the face and extremities secondary to pemetrexed
por: Doyle, Thomas, et al.
Publicado: (2023)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study
por: Degens, Juliette, et al.
Publicado: (2020)

Pemetrexed for epithelioid haemangioendothelioma of the pleura
por: Kanemura, Shingo, et al.
Publicado: (2016)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up
por: Pruis, Melinda A., et al.
Publicado: (2023)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment
por: Otten, Leila S., et al.
Publicado: (2023)

Plasmodium berghei Δp52&p36 Parasites Develop Independent of a Parasitophorous Vacuole Membrane in Huh-7 Liver Cells
por: Ploemen, Ivo H. J., et al.
Publicado: (2012)

Eyelid and feet edema induced by pemetrexed
por: Kastalli, Sarrah, et al.
Publicado: (2016)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
por: Michalak, Olga, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lpmtqeqi84nb9tmdpg0qk8nm10